Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

Research and Innovation Action · Running

ENT1DEP Enterovirus-linked Type 1 Diabetes Exposed -mechanisms and Prevention

Coordinator
Tampereen Korkeakoulusaatio Sr, Finland
Runs
1 January 2024 to 31 December 2027
Status
Running
EU funding
€7.1m
Total cost
€7.1m
Partners
14 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101137457

What the project is doing

In the project's own words, from its summary on CORDIS.

ENT1DEP aims to define causal links between infections and NCDs by focusing on enterovirus (EV) infections and type 1 diabetes (T1D), a robust association without proof of causality. Causality is addressed by a multidisciplinary, multi-layer approach, using in-vitro and in-vivo models, unique human samples, and artificial intelligence to identify mechanisms and related biomarkers, asking 3 key questions:1. Why are only insulin-producing β-cells destroyed by EVs?

Weak β-cell antiviral responses and high expression of EV entry receptors may favour EV persistence. This hypothesis is addressed using human cell models (stem-cell-derived β/α-cells, organoids, their genetic modifications, anti-EV T-cells) and pancreas tissues from T1D patients.2. Why do only some individuals develop T1D after EV infection? Weak EV immunity may predispose to virus spreading to pancreas, persistence and local inflammation, triggering autoimmunity.

This hypothesis is addressed by analysing adaptive and innate immune responses to EVs, correlating these with gene polymorphisms and EV persistence in children followed from birth and who developed T1D.3. How can EV-associated T1D risk be attenuated? By using vaccines inducing protective immunity and antiviral drugs eradicating persistent infection. This hypothesis is addressed by examining samples from pioneering EV vaccine and T1D antiviral trials to develop biomarkers of vaccine- vs infection-induced immunity as surrogates of vaccine efficacy; by studying whether vaccine-induced antibodies prevent EV-induced diabetes in mice; by correlating antiviral treatment with EV clearance and immunity to identify biomarkers for EV eradication and patient selection.

The final goal is to identify individuals at risk for EV-induced T1D as targets for early interventions. These outcomes may also facilitate progress in other NCDs extending impact. This new knowledge is disseminated among stakeholders to facilitate optimal NCD prevention and treatment.

Topics

Who is involved

OrganisationCityCountryRole
Tampereen Korkeakoulusaatio SrTampereFinlandCoordinator
The Walter and Eliza Hall Institute of Medical Research Public Companylimited by GuaranteeParkvilleAustraliaAssociatedpartner
University of New South WalesSydneyAustraliaAssociatedpartner
Empirica Gesellschaft Fur Kommunikations Und Technologieforschung MbhBonnGermanyParticipant
Tartu UlikoolTartuEstoniaParticipant
Helsingin YliopistoHelsinkiFinlandParticipant
Oulun YliopistoOuluFinlandParticipant
Pirkanmaan HyvinvointialueTampereFinlandParticipant
Turun YliopistoTurkuFinlandParticipant
Vactech OyTampereFinlandParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Sanofi R&d VaccinsLyonFranceParticipant
Oslo Universitetssykehus HfOsloNorwayParticipant
Karolinska InstitutetStockholmSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI